Načítá se...
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F(2α) receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrate...
Uloženo v:
| Vydáno v: | Clin Ophthalmol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5079698/ https://ncbi.nlm.nih.gov/pubmed/27799730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S103985 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|